Kala Pharmaceuticals, Inc.
Quick facts
Phase 3 pipeline
- KPI-121 0.25% · Ophthalmology
KPI-121 is a topical ophthalmic formulation that reduces ocular surface inflammation and promotes tear film stability through a mucoadhesive delivery system. - KPI-121 0.25% Ophthalmic Suspension · Ophthalmology
KPI-121 is a suspension formulation designed to reduce ocular inflammation and improve tear film stability in dry eye disease through sustained ocular surface contact. - KPI-121 1.0% · Ophthalmology
KPI-121 is a topical ophthalmic formulation that reduces ocular surface inflammation and promotes tear film stability through a mucoadhesive delivery system. - KPI-121 Ophthalmic Suspension · Ophthalmology
KPI-121 is a topical ophthalmic suspension that reduces ocular inflammation and promotes corneal healing through inhibition of transient receptor potential vanilloid 1 (TRPV1) and modulation of inflammatory pathways. - Vehicle of KPI-121 0.25% · Ophthalmology
KPI-121 is a corticosteroid - Vehicle of KPI-121 1.0% · Ophthalmology
KPI-121 is a corticosteroid
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: